Cargando…

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice

Chronic kidney disease (CKD) affects around 10% of the global population and is most often caused by diabetes. Diabetes with CKD (diabetic kidney disease, DKD) is a progressive condition that may cause kidney failure and which contributes significantly to the excess morbidity and mortality in these...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Scholten, Bernt Johan, Kreiner, Frederik Flindt, Rasmussen, Søren, Rossing, Peter, Idorn, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Diabetic Kidney Disease: Pathogenesis and Therapeutic Targets
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301118/ https://www.ncbi.nlm.nih.gov/pubmed/35874312 http://dx.doi.org/10.1177/20420188221112490

Ejemplares similares

Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
por: Mallik, Ritwika, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?
por: Ujjawal, Aditi, et al.
Publicado: (2022)

Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes
por: de Bhailís, Áine M., et al.
Publicado: (2021)

Examining the factors contributing to the association between non-albuminuric CKD and a low rate of kidney function decline in diabetes
por: Buyadaa, Oyunchimeg, et al.
Publicado: (2022)

Association between the metabolic profile of serum fatty acids and diabetic nephropathy: a study conducted in northeastern China
por: Liu, Yazhuo, et al.
Publicado: (2022)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023)

The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients
por: Kukla, Aleksandra, et al.
Publicado: (2020)

Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view
por: Pinier, Cédric, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center
por: Yuan, Christina M., et al.
Publicado: (2017)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

Insulin at 100: still central in protein-based therapy for chronic disease
por: Kurtzhals, Peter, et al.
Publicado: (2021)

The large spectrum of renal disease in diabetic patients
por: Bermejo, Sheila, et al.
Publicado: (2017)

The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
por: Sarafidis, Pantelis A, et al.
Publicado: (2019)

Diabetes mellitus: a single cardiorenal syndrome umbrella
por: Rodríguez, Eva, et al.
Publicado: (2019)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
por: Friedrichsen, Martin Haljeta, et al.
Publicado: (2023)

Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?
por: Christensen, Regitse Højgaard, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Chronic kidney disease in children
por: Becherucci, Francesca, et al.
Publicado: (2016)

Effects of GLP‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysis
por: Kelly, Michael, et al.
Publicado: (2022)

Potential and pitfalls in the genetic diagnosis of kidney diseases
por: Kesselheim, Anne, et al.
Publicado: (2017)

Electronic patient-reported outcomes in clinical kidney practice (ePRO Kidney): a process evaluation of educational support for clinicians
por: Schick-Makaroff, Kara, et al.
Publicado: (2023)

Consequences of morbid obesity on the kidney. Where are we going?
por: Navarro Díaz, Maruja
Publicado: (2016)

HIV and kidney diseases: 35 years of history and consequences
por: Campos, Pedro, et al.
Publicado: (2016)

Incident chronic kidney disease: trends in management and outcomes
por: Perkins, Robert M., et al.
Publicado: (2016)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Chronic kidney disease hotspots in developing countries in South Asia
por: Abraham, Georgi, et al.
Publicado: (2016)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Impact of routine reporting of estimated glomerular filtration rate using the European Kidney Function Consortium and Chronic Kidney Disease Epidemiology Collaboration equations in a Western Australian community population
por: Napier, Kathryn, et al.
Publicado: (2022)

Patient kidney disease knowledge remains inadequate with standard nephrology outpatient care
por: Gray, Nicholas A., et al.
Publicado: (2016)

Safety concerns about intravenous iron therapy in patients with chronic kidney disease
por: Del Vecchio, Lucia, et al.
Publicado: (2016)

Noninvasive markers of arterial stiffness and renal outcomes in patients with chronic kidney disease
por: Guo, Xinru, et al.
Publicado: (2021)

Chronic kidney disease in public renal practices in Queensland, Australia, 2011–2018
por: Hoy, Wendy E., et al.
Publicado: (2022)

Two brothers with identical variants of the CLCN5 gene—one developing Dent’s disease
por: Fischer, Anne Sophie, et al.
Publicado: (2018)

High prevalence of chronic kidney disease in a semi-urban population of Western India
por: Trivedi, Hargovind, et al.
Publicado: (2016)

Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk
por: Wilson, Scott, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease
por: Cai, Xiaoyan, et al.
Publicado: (2021)

Effect of large weight reductions on measured and estimated kidney function
por: von Scholten, Bernt Johan, et al.
Publicado: (2017)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gr4df3ur1cucg2mdvttqpv561q